HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) w

Inhibrx Biosciences (NASDAQ: INBX - Get Free Report) and Connect Biopharma (NASDAQ: CNTB - Get Free

Connect Biopharma NASDAQ: CNTB reported top-line results from its Seabreeze STAT Phase II study of r

HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) w

Gainers Monte Rosa Therapeutics (NASDAQ:GLUE) stock rose 9.7% to $13.09 during Wednesday's afte

U.S. stocks mixed: Dow fell over 200 points, while Nasdaq and S&P 500 rose; inflation cooled and

Connect Biopharma Holdings Limited (NASDAQ:CNTB) recently shared positive topline results from its g

Connect Biopharma reports positive Phase 2 results for rademikibart, showing an 81% reduction in COP

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Seabreeze STAT Study Evaluati

Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 147.1% to $0.18 during Wednesday'

BTIG analyst Julian Harrison maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and lower

U.S. stocks rose, led by tech, as Jabil beat Q4 estimates and raised FY2027 guidance; oil and gold a

Gainers NewGenIvf Group (NASDAQ:NIVF) shares moved upwards by 106.0% to $0.15 during Wednesday'

Key topline results include:Rademikibart significantly reduced the rate of treatment failure by 81%

– Rademikibart significantly reduced the rate of treatment failure compared to placebo through one m

Oppenheimer analyst Mazahir Alimohamed maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Out

HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) w

Canaccord Genuity analyst Edward Nash maintains Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy

Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study fo

Gainers PDS Biotechnology (NASDAQ:PDSB) shares rose 63.7% to $0.65 during Tuesday's regular ses

BTIG analyst Julian Harrison reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) with a Buy and main

Connect Biopharma Holdings Limited (NASDAQ:CNTB) stock hit its 52-week low on Tuesday after releasin

Connect Biopharma asthma drug rademikibart misses primary endpoint but shows improved lung function

Gainers Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 39.3% to $1.56 during Tuesday

Connect Biopharma Holdings Limited (NASDAQ:CNTB) (Connect Biopharma, Connect or the Company), a clin

– Rademikibart meaningfully reduced the rate of treatment failure at 28 days by 66% compared to plac

Gainers Basel Medical Group (NASDAQ:BMGL) shares moved upwards by 59.8% to $7.32 during Monday'

SAN DIEGO, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con

Gainers Autonomix Medical (NASDAQ:AMIX) stock moved upwards by 142.1% to $13.0 during Monday's

– Completed enrollment in Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD

Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ: CNTB - Get Free Report) has been assigned

CNTB is developing rademikibart, a drug with a similar mechanism of action to SNY/REGN's blockbuster

Oppenheimer analyst Mazahir Alimohamed initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB

Piper Sandler analyst Biren Amin initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB) with

HC Wainwright & Co. analyst Brandon Folkes reiterates Connect Biopharma Hldgs (NASDAQ:CNTB) w

– On track to also complete enrollment in the Seabreeze STAT COPD study this month –– Expect to repo

– On track to also complete enrollment in the Seabreeze STAT COPD study this month – – Expect to rep

Top Wall Street analysts changed outlook on top names. See analyst ratings page for all changes. Ana

Canaccord Genuity analyst Edward Nash initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNTB)

Connect Biopharma NASDAQ: CNTB Chief Executive Officer Barry Quart said the company's rademikibart p

Cantor Fitzgerald analyst Olivia Brayer initiates coverage on Connect Biopharma Hldgs (NASDAQ:CNT

SAN DIEGO, May 12, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Conne

Connect Biopharma Hldgs (NASDAQ:CNTB) reported quarterly losses of $(0.34) per share which missed th

– Phase 2 Seabreeze STAT studies for acute exacerbations in asthma and COPD continuing as planned ba

Connect Biopharma Holdings is rated a risky Buy, with high upside potential hinging on mid-2026 Phas

The independent DMC reviewed interim data based on a pre-specified analysis of treatment failure at

SAN DIEGO, April 23, 2026 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Con